124 related articles for article (PubMed ID: 23556445)
1. Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy.
Tafrali C; Paizi A; Borg J; Radmilovic M; Bartsakoulia M; Giannopoulou E; Giannakopoulou O; Stojiljkovic-Petrovic M; Zukic B; Poulas K; Stavrou EF; Lambropoulou P; Kourakli A; Felice AE; Papachatzopoulou A; Philipsen S; Pavlovic S; Georgitsi M; Patrinos GP
Pharmacogenomics; 2013 Apr; 14(5):469-83. PubMed ID: 23556445
[TBL] [Abstract][Full Text] [Related]
2. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
[TBL] [Abstract][Full Text] [Related]
3. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
[No Abstract] [Full Text] [Related]
4. Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.
Pecoraro A; Rigano P; Troia A; Calzolari R; Scazzone C; Maggio A; Steinberg MH; Di Marzo R
Eur J Haematol; 2014 Jan; 92(1):66-72. PubMed ID: 24112139
[TBL] [Abstract][Full Text] [Related]
5. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
[TBL] [Abstract][Full Text] [Related]
6. Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea.
Chondrou V; Stavrou EF; Markopoulos G; Kouraklis-Symeonidis A; Fotopoulos V; Symeonidis A; Vlachaki E; Chalkia P; Patrinos GP; Papachatzopoulou A; Sgourou A
Hum Genomics; 2018 Oct; 12(1):45. PubMed ID: 30285874
[TBL] [Abstract][Full Text] [Related]
7. Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients.
Chondrou V; Kolovos P; Sgourou A; Kourakli A; Pavlidaki A; Kastrinou V; John A; Symeonidis A; Ali BR; Papachatzopoulou A; Katsila T; Patrinos GP
Hum Genomics; 2017 Oct; 11(1):24. PubMed ID: 29061162
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea in thalassemia intermedia--a promising therapy.
Dixit A; Chatterjee TC; Mishra P; Choudhry DR; Mahapatra M; Tyagi S; Kabra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Jul; 84(7):441-6. PubMed ID: 15838670
[TBL] [Abstract][Full Text] [Related]
9. Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India.
Italia KY; Jijina FJ; Merchant R; Panjwani S; Nadkarni AH; Sawant PM; Nair SB; Ghosh K; Colah RB
Clin Chim Acta; 2009 Sep; 407(1-2):10-5. PubMed ID: 19545554
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening.
Alebouyeh M; Moussavi F; Haddad-Deylami H; Vossough P
Ann Hematol; 2004 Jul; 83(7):430-3. PubMed ID: 14722738
[TBL] [Abstract][Full Text] [Related]
11. A single nucleotide polymorphism in the HBBP1 gene in the human β-globin locus is associated with a mild β-thalassemia disease phenotype.
Giannopoulou E; Bartsakoulia M; Tafrali C; Kourakli A; Poulas K; Stavrou EF; Papachatzopoulou A; Georgitsi M; Patrinos GP
Hemoglobin; 2012; 36(5):433-45. PubMed ID: 22943111
[TBL] [Abstract][Full Text] [Related]
12. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
Mtvarelidze Z; Kvezereli-Kopadze A; Kvezereli-Kopadze M; Mestiashvili I
Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
Watanapokasin R; Sanmund D; Winichagoon P; Muta K; Fucharoen S
Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
[TBL] [Abstract][Full Text] [Related]
15. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
[TBL] [Abstract][Full Text] [Related]
17. Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients.
Gravia A; Chondrou V; Sgourou A; Papantoni I; Borg J; Katsila T; Papachatzopoulou A; Patrinos GP
Pharmacogenomics; 2014 Jul; 15(10):1355-64. PubMed ID: 25155936
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?
Banan M
Ann Hematol; 2013 Mar; 92(3):289-99. PubMed ID: 23318979
[TBL] [Abstract][Full Text] [Related]
19. Treatment of beta-thalassemia with hydroxyurea (HU)--effects of HU on globin gene expression.
Huang SZ; Ren ZR; Chen MJ; Xu HP; Zeng YT; Rodgers GP; Zeng FY; Schechter AN
Sci China B; 1994 Nov; 37(11):1350-9. PubMed ID: 7865126
[TBL] [Abstract][Full Text] [Related]
20. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
